{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:58:49Z","timestamp":1761461929280,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.coph.2022.102270","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T17:34:53Z","timestamp":1659288893000},"page":"102270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["New developments in treatments for systemic vasculitis"],"prefix":"10.1016","volume":"66","author":[{"given":"Sarah","family":"Goglin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2238-2287","authenticated-orcid":false,"given":"Sharon A.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102270_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102270_bib2","first-page":"S94","article-title":"Mortality in systemic vasculitis: a systematic review","volume":"26","author":"Phillip","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coph.2022.102270_sref3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of rheumatology\/vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102270_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.semarthrit.2016.10.001","article-title":"Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis","volume":"46","author":"Wilson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102270_bib5","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102270_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2022.102270_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A\u00a0double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102270_bib8","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102270_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102270_bib10","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/rheumatology\/keab780","article-title":"New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension","volume":"61","author":"Stone","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.coph.2022.102270_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A\u00a0randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102270_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.24200","article-title":"Ustekinumab for the treatment of giant cell arteritis","volume":"73","author":"Matza","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coph.2022.102270_bib13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","article-title":"Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial","volume":"48","author":"Conway","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102270_bib14","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102270_bib15","article-title":"Secukinumab in giant cell arteritis: a randomized, parallel-group, double-blind, placebo-controlled, multicenter phase 2 trial [abstract]","volume":"73","author":"Venhoff","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102270_bib16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102270_bib17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Systemic Vasculitis Study Group of the Italian Society for R: prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2022.102270_bib18","first-page":"395","article-title":"Systemic Vasculitis Study Group of the Italian Society for R: long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids","volume":"26","author":"Cimmino","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coph.2022.102270_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2022.102270_bib20","doi-asserted-by":"crossref","first-page":"R176","DOI":"10.1186\/ar3140","article-title":"Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial","volume":"12","author":"Kreiner","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coph.2022.102270_bib21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.semarthrit.2019.12.005","article-title":"Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102270_sref22","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102270_sref23","doi-asserted-by":"crossref","first-page":"E758","DOI":"10.1016\/S2665-9913(21)00245-9","article-title":"Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial","volume":"3","author":"Marsman","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coph.2022.102270_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102270_bib25","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102270_bib26","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102270_sref27","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102270_sref28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102270_sref29","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2022.102270_sref30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102270_bib31","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.coph.2022.102270_sref32","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"Br Med J"},{"key":"10.1016\/j.coph.2022.102270_sref33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-Term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2022.102270_bib34","article-title":"Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: a double-blind, randomized, controlled trial [abstract]","volume":"73","author":"Terrier","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102270_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.coph.2022.102270_bib36","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102270_bib37","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.coph.2022.102270_bib38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1183\/23120541.00451-2020","article-title":"Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Nanzer","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.coph.2022.102270_bib39","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.coph.2022.102270_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00311-2019","article-title":"Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Kent","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.coph.2022.102270_bib41","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102270_bib42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102270_bib43","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2022.102270_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102270_bib45","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2022.102270_bib46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/acr2.11274","article-title":"Comparison of two rituximab induction regimens for antineutrophil cytoplasm antibody\u2013associated vasculitis: systematic review and meta-analysis","volume":"3","author":"B\u00e9nard","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.coph.2022.102270_bib47","article-title":"A\u00a0randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract]","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102270_bib48","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2215\/CJN.07340713","article-title":"Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:55:51Z","timestamp":1761461751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":48,"alternative-id":["S1471489222000972"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102270","relation":{},"ISSN":["1471-4892"],"issn-type":[{"type":"print","value":"1471-4892"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New developments in treatments for systemic vasculitis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102270"}}